Wednesday, April 13, 2016

A Decades-Old Study, Rediscovered, Challenges Advice on Saturated Fat




Photo
CreditTony Cenicola/The New York Times
A four-decades-old study — recently discovered in a dusty basement — has raised new questions about longstanding dietary advice and the perils of saturated fat in the American diet.
The research, known as the Minnesota Coronary Experiment, was a major controlled clinical trial conducted from 1968 to 1973, which studied the diets of more than 9,000 people at state mental hospitals and a nursing home.
During the study, which was paid for by the National Heart, Lung and Blood Institute and led by Dr. Ivan Frantz Jr. of the University of Minnesota Medical School, researchers were able to tightly regulate the diets of the institutionalized study subjects. Half of those subjects were fed meals rich in saturated fats from milk, cheese and beef. The remaining group ate a diet in which much of the saturated fat was removed and replaced with corn oil, an unsaturated fat that is common in many processed foods today. The study was intended to show that removing saturated fat from people’s diets and replacing it with polyunsaturated fat from vegetable oils would protect them against heart disease and lower their mortality.
So what was the result? Despite being one of the largest controlled clinical dietary trials of its kind ever conducted, the data were never fully analyzed.
Several years ago, Christopher E. Ramsden, a medical investigator at the National Institutes of Health, learned about the long-overlooked study. Intrigued, he contacted the University of Minnesota in hopes of reviewing the unpublished data. Dr. Frantz, who died in 2009, had been a prominent scientist at the university, where he studied the link between saturated fat and heart disease. One of his closest colleagues was Ancel Keys, an influential scientist whose research in the 1950s helped establish saturated fat as public health enemy No. 1, prompting the federal government to recommend low-fat diets to the entire nation.
“My father definitely believed in reducing saturated fats, and I grew up that way,” said Dr. Robert Frantz, the lead researcher’s son and a cardiologist at the Mayo Clinic. “We followed a relatively low-fat diet at home, and on Sundays or special occasions, we’d have bacon and eggs.”
The younger Dr. Frantz made three trips to the family home, finally discovering the dusty box marked “Minnesota Coronary Survey,” in his father’s basement. He turned it over to Dr. Ramsden for analysis.
The results were a surprise. Participants who ate a diet low in saturated fat and enriched with corn oil reduced their cholesterol by an average of 14 percent, compared with a change of just 1 percent in the control group. But the low-saturated fat diet did not reduce mortality. In fact, the study found that the greater the drop in cholesterol, the higher the risk of death during the trial.
The findings run counter to conventional dietary recommendations that advise a diet low in saturated fat to decrease heart risk. Current dietary guidelines call for Americans to replace saturated fat, which tends to raise cholesterol, with vegetable oils and other polyunsaturated fats, which lower cholesterol.
While it is unclear why the trial data had not previously been fully analyzed, one possibility is that Dr. Frantz and his colleagues faced resistance from medical journals at a time when questioning the link between saturated fat and disease was deeply unpopular.
“It could be that they tried to publish all of their results but had a hard time getting them published,” said Daisy Zamora, an author of the new study and a research scientist at the University of North Carolina at Chapel Hill.
The younger Dr. Frantz said his father was probably startled by what seemed to be no benefit in replacing saturated fat with vegetable oil.
“When it turned out that it didn’t reduce risk, it was quite puzzling,” he said. “And since it was effective in lowering cholesterol, it was weird.”
The new analysis, published on Tuesday in the journal BMJ, elicited a sharp response from top nutrition experts, who said the study was flawed. Walter Willett, the chairman of the nutrition department at the Harvard T.H. Chan School of Public Health, called the research “irrelevant to current dietary recommendations” that emphasize replacing saturated fat with polyunsaturated fat.
Frank Hu, a nutrition expert who served on the government’s 2015 dietary guidelines committee, said the Minnesota trial was not long enough to show the cardiovascular benefits of consuming vegetable oil because the patients on average were followed for only about 15 months. He pointed to a major 2010 meta-analysis that found that people had fewer heart attacks when they increased their intake of vegetable oils and other polyunsaturated fats over at least four years.
“I don’t think the authors’ strong conclusions are supported by the data,” he said.
To investigate whether the new findings were a fluke, Dr. Zamora and her colleagues analyzed four similar, rigorous trials that tested the effects of replacing saturated fat with vegetable oils rich in linoleic acid. Those, too, failed to show any reduction in mortality from heart disease.
“One would expect that the more you lowered cholesterol, the better the outcome,” Dr. Ramsden said. “But in this case the opposite association was found. The greater degree of cholesterol-lowering was associated with a higher, rather than a lower, risk of death.”
One explanation for the surprise finding may be omega-6 fatty acids, which are found in high levels in corn, soybean, cottonseed and sunflower oils. While leading nutrition experts point to ample evidence that cooking with these vegetable oils instead of butter improves cholesterol and prevents heart disease, others argue that high levels of omega-6 can simultaneously promote inflammation. This inflammation could outweigh the benefits of cholesterol reduction, they say.
In 2013, Dr. Ramsden and his colleagues published a controversial paper about a large clinical trial that had been carried out in Australia in the 1960s but had never been fully analyzed. The trial found that men who replaced saturated fat with omega-6-rich polyunsaturated fats lowered their cholesterol. But they were also more likely to die from a heart attack than a control group of men who ate more saturated fat.
Ron Krauss, the former chairman of the American Heart Association’s dietary guidelines committee, said the new research was intriguing. But he said there was a vast body of research supporting polyunsaturated fats for heart health, and that the relationship between cholesterol-lowering and mortality could be deceiving.
People who have high LDL cholesterol, the so-called bad kind, typically experience greater drops in cholesterol in response to dietary changes than people with lower LDL. Perhaps people in the new study who had the greatest drop in cholesterol also had higher mortality rates because they had more underlying disease.
“It’s possible that the greater cholesterol response was in people who had more vascular risk related to their higher cholesterol levels,” he said.
Dr. Ramsden stressed that the findings by he and his colleagues should be interpreted cautiously. The research does not show that saturated fats are beneficial, he said: “But maybe they’re not as bad as people thought.”
The research underscores that the science behind dietary fat may be more complex than nutrition recommendations suggest. The body requires omega-6 fats like linoleic acid in small amounts. But emerging research suggests that in excess linoleic acid may play a role in a variety of disorders including liver disease and chronic pain.
A century ago, it was common for Americans to get about 2 percent of their daily calories from linoleic acid. Today, Americans on average consume more than triple that amount, much of it from processed foods like lunch meats, salad dressings, desserts, pizza, french fries and packaged snacks like potato chips. More natural sources of fat such as olive oil, butter and egg yolks contain linoleic acid as well but in smaller quantities.
Eating whole, unprocessed foods and plants may be one way to get all the linoleic acid your body needs, Dr. Ramsden said.
article

Friday, April 8, 2016

Model in Gucci Ad Is Deemed ‘Unhealthily Thin’ by British Regulator




Photo

The Advertising Standards Authority in Britain ruled that this model in a Gucci ad looked “unhealthily thin.”CreditGucci, via The ASA

LONDON — The model in the Gucci ad is young and waiflike, her frail body draped in a geometric-pattern dress as she leans back in front of a wall painted with a tree branch that appears to mimic the angle of her silhouette.
On Wednesday, the Advertising Standards Authority of Britain ruled that the ad was “irresponsible” and that the model looked “unhealthily thin,” fanning a perennial debate in the fashion industry over when thin is too thin.
The regulator said that the way the woman in the image had posed elongated her torso and accentuated her waist, so that it appeared to be very small. It said her “somber facial expression and dark makeup, particularly around her eyes, made her face look gaunt.” It said the offending image — a still photograph of the model that appeared in an online video posted on the website of The Times of London in December — should not appear again in its current form.
The specific image was removed from the video on Gucci’s YouTube channel, though the model still appears in the ad directed by Glen Luchford.
The Italian fashion brand, for its part, had defended the ad, saying it was part of a video that portrayed a dance party and that was aimed at an older and sophisticated audience. Nowhere in the ads were any models’ bones visible, it said, and they were all “toned and slim.” It noted that “it was, to some extent, a subjective issue as to whether a model looked unhealthily thin,” according to the authority.




The decision by the advertising authority, an independent industry regulatory group, barred Gucci from using the image in advertisements in Britain. The ruling comes amid a longstanding debate on both sides of the Atlantic about the perils of overly thin models projecting an unhealthy body image for women. As when critics lashed out against idealized images of “heroin chic” in the early 1990s, some have voiced concern that fashion houses are encouraging potentially hazardous behaviors by glamorizing models who are rail-thin.
Last year, the French Parliament approved measures prohibiting modeling agencies from hiring dangerously thin models and requiring altered photographs of models to be clearly labeled. Under the law, models need a doctor’s certificate to certify they are fit to work, and employers could be jailed or fined 75,000 euros, or about $85,000, if the rules are breached.
The measures were intended to prevent young and vulnerable models from being pressed into becoming excessively thin, to protect against anorexiaand to push back against images of unhealthily thin women featured in glossy fashion magazines.
At the time, some modeling agencies criticized the law, saying it was wrong to link the thinness of models to anorexia without looking at the full spectrum of symptoms. “It is very serious to conflate anorexia and the thinness of models,” Isabelle Saint-FĂ©lix, secretary general of the National Union of Modeling Agencies, told Agence France-Presse at the time.
Last year, the Advertising Standards Authority ruled against an Yves Saint Laurent ad that featured a model with pipe cleaner-like legs lying on the floor. The authority said the model appeared “unhealthily underweight,” with a visible rib cage and very thin legs.

article

Friday, April 1, 2016

New F.D.A. Guidelines Ease Access to Abortion Pill






Photo

Demonstrators at the Supreme Court building on March 2 when the court heard arguments in a major abortion case. The F.D.A. on Wednesday eased some requirements for taking a medication that induces abortion. CreditGabriella Demczuk for The New York Times

The Food and Drug Administration has relaxed the guidelines for taking a pill that induces abortion, reviving one of the most contentious issues of the abortion debate. The change allows women to use the drug further into pregnancy and with fewer visits to the doctor.
The announcement on Wednesday came unexpectedly in the final stretch of the Obama administration and amid an election campaign in which both parties covet the women’s vote. Some abortion opponents charged that the new regimen was politically motivated. The F.D.A. said its actions were based strictly on medical science.
The change was an unequivocal victory for abortion rights advocates who had been fighting laws in Texas, North Dakota and Ohio, among other states, that require doctors prescribing the pill to follow the directions on the F.D.A. label for using it, which had been more stringent.
The change brings the directions for taking the drug, mifepristone, in line with what has become standard medical practice in most states: reducing the dosage to 200 milligrams from 600 milligrams, decreasing the number of visits a woman must make to a doctor to two from three, and extending the period when she can take the pill to 10 weeks ofpregnancy from seven weeks.
The debate over the drug, formerly known as RU-486, has raged for decades, with abortion rights groups demanding access to it in the United States in the 1990s. Medication-induced abortions have increasingly been used to terminate pregnancies in recent years, and limiting access to them has become an important front in the anti-abortion movement. They made up as much as a quarter of all abortions in 2011, according to the most recent figures from the Guttmacher Institute, which tracks women’s reproductive health issues. Planned Parenthood said as many as half of eligible women in its clinics requested medication-induced abortions.
The original label on the drug was based on clinical evidence from the 1990s before the pill was approved in 2000. Doctors said that new evidence had emerged supporting lower doses, which have fewer side effects, and a longer period in which women could take the medication safely. In most states, doctors have been following the medically accepted regimen, even though the label advised otherwise, a fairly common medical practice known as off-label use.


Photo

Mifeprex, a medication that induces abortion. The F.D.A. on Wednesday relaxed the requirements on use of the drug.

“This is a major shift both in closing the gap between science and legal regulation and in enabling women to exercise their constitutional right to terminate a pregnancy,” said Suzanne B. Goldberg, a law professor at Columbia University who specializes in sexuality and gender law.
The American Congress of Obstetricians and Gynecologists said in a statement that it was “pleased that the updated F.D.A.-approved regimen for mifepristone reflects the current available scientific evidence and best practices.”
Anti-abortion groups said that the change did nothing to improve safety for women, and that some women fell ill or died after taking the drug. (A spokeswoman for the company that makes the drug, Danco Laboratories, said there was no proof it caused the deaths.)
“It appears this has been done for the convenience and the profitability of the abortion industry,” said Randall O’Bannon, the director of education and research for the National Right to Life Committee.
Eric Scheidler, the executive director of the Pro-Life Action League, an anti-abortion group based in Chicago, said, “My first thought was that this is a bone that the Obama administration was throwing out there to their friends in the abortion lobby.”
The drug works by blocking receptors of progesterone, an important hormone in pregnancy. Women have to get the drug from a medical provider. They can also get another drug, misoprostol, in the same first visit to the provider, according to the new label. Together, the drugs induce miscarriage. The label still requires a “follow-up with the health care provider,” but some abortion rights advocates said that could be interpreted as a lab test or something that did not require a visit to a doctor.
Many states have passed laws to restrict the use of mifepristone since its F.D.A. approval. Some of them require medical professionals who administer the drug to be licensed physicians, rather than nurses or physician assistants. Many states also require the prescribing doctor to be present with the patient, a rule that abortion rights advocates say blocks women in rural areas from receiving the medication remotely.


Sign Up for the Science Times Newsletter

Every week, we'll bring you stories that capture the wonders of the human body, nature and the cosmos.

Laws requiring physicians to adhere to the guidelines on the label have also passed in Arkansas, Oklahoma, and Arizona, but have been blocked by court order.
It was not immediately clear what the change would mean for state laws and the future of the legal effort by anti-abortion groups. Kristi Hamrick, a spokeswoman for Americans United for Life, an organization that drafts model legislation seeking to regulate the drugs, said, “This is just Day 1, and so our lawyers are looking at it.” The F.D.A. said it had followed regulatory procedure in changing the label. Danco submitted an application last May, and the application was subject to a 10-month review period, which ended March 29, the agency said.
“Honestly, I think the timing was based on when the company put in the application for a label change, not based on election timing,” said Susan Wood, the director of the Jacobs Institute of Women’s Health at the Milken Institute School of Public Health at George Washington University. “The F.D.A. just responded as part of their regulatory responsibilities, not on a political time frame.”
In Texas, abortion providers applauded the change.
“This will allow us to do two things immediately: Expand medical abortions up to 10 weeks of pregnancy, and cut out the unnecessary additional visit for the second dose of medication,” said Amy Hagstrom Miller, the president of Whole Woman’s Health, which has abortion facilities in five states including Texas and is the lead plaintiff in an abortion case before the Supreme Court.
More than 40 percent of patients at the group’s Texas clinics chose medication abortions before Texas passed a law in 2013, requiring, among other things, that doctors follow the F.D.A.’s protocol. Since then, only about 5 percent have, she said.
Dr. Raegan McDonald-Mosley, the chief medical officer of Planned Parenthood Federation of America, said the change would reduce confusion among patients who had to sign two sets of consent forms, one with the regimen recommended by much of medical science and one that detailed the requirements on the F.D.A. label.
“Now those two things are in sync,” she said.

Team of Rival Scientists Comes Together to Fight Zika

Photo
A female Aedes aegypti mosquito takes a “blood meal” from Ben Matthews, a postdoctoral fellow at Rockefeller University. Dozens of her offspring, all fathered by a single male, were the source of the DNA needed to create a new genome map with modern sequencing and assembly techniques.CreditHilary Swift for The New York Times
With the Zika virus spreading largely unchecked in Latin America and the Caribbean by way of a now-notorious insect, some of the nation’s leading mosquito researchers are striving to assemble a state-of-the-art DNA map that they say will help them fight the disease with the mosquito’s own genetic code.
The quest involves scientists from assorted disciplines who rarely collaborate, often compete for funding and have different ideas about how to genetically manipulate the mosquito, Aedes aegypti.
Some want to hunt for genes that, if altered in mosquitoes released into the wild, could drive the species to extinction. Others are trying to identify genes that control how mosquitoes sense human prey so as to devise better repellents. Still others favor the idea of selectively breeding populations of mosquitoes, like corn or cattle, for desirable — or, at least, less undesirable — traits, such as a preference for biting animals other than humans.
The project took off after a series of frustrated Twitter posts from Leslie B. Vosshall, a mosquito researcher at Rockefeller University. Dr. Vosshall issued a plea for advice on constructing a detailed mosquito DNA map in January, as Brazil began reporting a spike, apparently related to the Zika virus, in newborns with unusually small heads.
“I was worried people would be defensive or paranoid or weird,” she said in the days leading up to the scientists’ first nine-way videoconference call. “For a long time, I think we all thought the map was somebody else’s job.”
The bid to map the genome of the Aedes mosquito has received little attention, perhaps because a map in itself will not yield a fix for Zika, any more than the human genome map has yielded a cure for cancer. It might lead to biological possibilities, moreover, whose ecological consequences are deemed too serious to risk.
But the story of how the Aedes Genome Working Group emerged offers a glimpse at the often ad hoc way science lurches forward, driven by self-interest, new technology and pressing social needs. The pursuits of its members reflect the range of hopes for a new form of genetic combat that may be increasingly called into play as the specter of diseases borne by insects grows along with our ability to parse the details of their DNA.
And the need to control the Aedes mosquito, which also carries yellow fever and other viruses, is not likely to end with this outbreak. Despite the introduction of a vaccine against yellow fever that saved millions of lives, for instance, the virus still kills 30,000 people a year.
“If we’re going to control the creature, we need to know it frontwards and backwards,” said Jeffrey Powell, a mosquito researcher at Yale University, who was among the first to join forces with Dr. Vosshall. “Having a complete genome sequence of the beast will give us a fundamental understanding of its biology that you can’t get any other way.”

A Powerful Tool

Genome mapping, which first captured the public imagination in 2000 with the release of a draft of the human DNA sequence, has become a fundamental tool of modern molecular biology, used to help study how living things evolve, develop, get sick and behave. An Aedes genome map of sorts, too, has existed since 2007, but researchers say it is staggeringly imperfect: fragmented into 36,204 pieces, some of which are themselves misassembled, with hundreds of genes known to be missing and others mistakenly duplicated.
Photo
The participants in the Aedes Genome Working Group held a nine-way videoconference call in January, led by Leslie B. Vosshall, top center.
For a long time, cost and sheer difficulty made filling in every detail prohibitive for all but a few genome sequences, including our own and those of a handful of laboratory favorites like mice and fruit flies. Even as new techniques have made it easier and more affordable to create better maps, the task has been seen more as a technical feat than a scientific one, which is one reason the Aedes map has remained in its state of disrepair.
“There’s not a lot of glory in it,” Dr. Powell conceded.
Zika, however, has helped galvanize the small community of researchers who already spend most of their time thinking about the insect. The normally mild virus’s apparent link to brain damage in babies whose mothers were infected while pregnant has stirred fears worldwide and led health officials to declare the current pandemic a public health emergency.
An Aedes mosquito in the United States could become a carrier for the virus if the insect bit a traveler who had acquired Zika abroad. Though the use of air-conditioning and screens is likely to limit outbreaks in the United States as the mosquito population swells in the South this summer, stanching Zika’s spread means controlling a mosquito that has grown resistant to previously effective insecticides and requires only minute amounts of standing water to breed.
A few experiments with the mass release of biologically altered mosquitoes, carried out by a biotechnology company and by researchers funded by the Bill and Melinda Gates Foundation, have reportedly had some success. But researchers say other strategies are virtually certain to be needed. With the Obama administration asking for $1.8 billion to combat Zika, it seemed likely to Dr. Vosshall that the budget for a new map — a few hundred thousand dollars, with enough support and volunteer labor from other researchers — could somehow be secured.
And on their first videoconference call in late January, nine far-flung teams of scientists found common cause in their discontent with trying to track down which genes control which traits on a map that often leads them astray.
“I can’t tell you how many meetings I’ve been to where people use four-letter words” to describe the existing map, Anthony A. James, a mosquito researcher at the University of California, Irvine, observed to the group.
Amid different opinions about the best approach and who would pay for what, a consensus emerged. The DNA for the new map would be extracted from the offspring of a very particular mating of Aedes mosquitoes, from the same line mapped a decade earlier.
A few days later, researchers at Virginia Tech shipped the offspring in the form of dried eggs to Dr. Vosshall’s laboratory at Rockefeller, where they were hatched and reared by a postdoctoral fellow, Ben Matthews. Since females will not lay eggs until they are fed, Dr. Matthews took a necessary first step. Inside a humid chamber, behind an airlock and a third heavy door, he offered up his arm for a bite so that the selected Eve could take what is known in the parlance of mosquito researchers as “a blood meal.”
Continue reading the main story
“It’s kind of amazing,” he said cheerfully, “when you think about the amount of money, time and science that’s going to come downstream of this.”

An Age-Old Enemy

That a genome map for Aedes aegypti, however imperfect, was published in 2007 is a testament to the species’ longtime status as a potent human foe. (Its genus name, bestowed by 18th-century naturalists with a penchant for accuracy, means “unpleasant” in ancient Greek; “aegypti” refers to Egypt, where it was first believed to have been collected.)
Photo
A visualization of the recently sequenced Aedes aegypti genome. Each of the 3,752 colored lines is a fragment of its three chromosomes that could not be fit together without the additional information that the Aedes Genome Working Group hopes to produce. A 2007 genome map for Aedes aegypti is fragmented into about 10 times as many pieces. CreditMark Kunitomi
Besides Zika and yellow fever, the insect carries dengue, which causes a severe and sometimes fatal flulike illness, and chikungunya, which can cause intense joint pain that lasts for years.
Because Aedes is easier to maintain in laboratories, it is simpler to study than its more lethal cousins, certain Anopheles mosquitoes, which kill some 800,000 people a year by infecting them with malaria. The hope that scientists could blunt the threat of both species by learning which genes control what in Aedes was what persuaded the National Institutes of Health to underwrite the initial sequencing of the mosquito’s genome for about $18 million.
The genomes of every living thing consist of four chemical units that function like letters in an alphabet, arranged in sequences, or “words,” that tell its cells what to do. In Aedes’s case, each cell nucleus contains 1.3 billion letters of DNA from each parent, coiled into three chromosomes. Since the order of the words is also important, in an ideal world, a DNA sequence would consist of those same letters, which would then be assembled, or “mapped,” into three long stretches.
But the technology used for the 2007 Aedes map, and many others, could only read relatively short stretches of DNA at a time, which were then pieced together by matching up the sections where they overlapped in a process that often left some areas garbled and riddled with gaps. And since more than half of the Aedes genome consists of sequences that repeat again and again, it has proved more difficult than many genomes to make sense of.
“Have you seen ‘The Shining’?” Dr. Vosshall asked, referring to the classic horror film in which the psychotic Jack Torrance character, played by Jack Nicholson, appears to be writing a novel that turns out to be the same phrase over and over again. “It’s like you have a thousand copies of ‘all work and no play’ and then three sentences of unique text.”
Adam M. Phillippy, an expert in assembling genome maps at the National Institutes of Health, likened the process to doing a puzzle for which the pieces have precisely the same shape, are tiny, “and you’re missing the cover.”
But over the last few years, technology has emerged that allows the DNA letters to be read in stretches of tens of thousands at a time, making for bigger puzzle pieces and prompting biologists to revisit older genome maps.
Remapping the supposedly complete human genome with the new technique has yielded several previously unknown genes active in the brain that scientists say may hold clues to how we differ from other apes. The United States Agriculture Department is in the process of remapping pig, goat and cattle genomes in the expectation of finding genes that make for healthier and more efficient farm animals.
Evan E. Eichler, a human geneticist at the University of Washington who recently led a team in assembling a new gorilla genome, called the new information that scientists had been able to glean “mind-blowing.”
“There’s a strong case to be made for going back to the mosquito and redoing it,” he said, “like there is for any genome that still has lots of gaps.”
Photo
Dr. Matthews separated male and female Aedes aegypti mosquito larvae at Rockefeller University.CreditHilary Swift for The New York Times
Aware of the new technology, Dr. Vosshall floated the idea of a new Aedes map on Twitter: “The Aedes aegypti mosquito is infecting millions with #Zika and #Dengue,” she wrote on Jan. 28, “but we still haven’t put all the pieces of its genome together.”